Premium
Long‐term molecular remission with lenalidomide treatment of relapsed chronic lymphocytic leukemia
Author(s) -
Spina Francesco,
Rezzonico Francesca,
Farina Lucia,
Corradini Paolo
Publication year - 2013
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.12068
Subject(s) - lenalidomide , chronic lymphocytic leukemia , medicine , minimal residual disease , oncology , bone marrow , leukemia , immunology , gastroenterology , multiple myeloma
Lenalidomide is effective against relapsed chronic lymphocytic leukemia ( CLL ). We report the first case of long‐term molecular remission with continuous lenalidomide treatment in a young patient with CLL relapsed to multiple treatments. Minimal residual disease was assessed by nested polymerase chain reaction on bone marrow samples with patient‐specific primers. A 20‐yr‐old patient with standard‐risk CLL was treated with lenalidomide after multiple relapses and achieved a 4 yr long complete molecular response with minimal toxicities. Published biologic data support that lenalidomide induces an immune‐mediated control of CLL , and our case suggests that long‐term treatment with lenalidomide is effective at a molecular level in patients with relapsed CLL .